References
- Mauer A M. Therapy of acute lymphoblastic leukemia in childhood. Blood 1980; 56: 1–10
- Hamilton L, Elion G B. The fate of 6-mer-captopurine in man. Ann NY Acad Sci 1954; 60: 304–14
- Elion G B. Biochemistry and pharmacology of purine analogues. Fed Proc 1967; 26: 898–904
- Loo T L., Luce J K., Sullivan M P., Frei E, III. Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside. Clin Pharmacol Ther 1968; 9: 180–94
- Coffey J J., White C A., Lesk A B., Rogers W I., Serpick A A. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. Cancer Res 1972; 32: 1283–9
- Ding T L., Benet L Z. Determination of 6-mercaptopurine and azathioprine in plasma by high-performance liquid chromatography. J Chromatogr 1979; 163: 281–8
- Maddocks J L. Assay of azathioprine 6-mercaptopurine and a novel thiopurine metabolite in human plasma. Br J Clin Pharmacol 1979; 8: 273–8
- Lin S-N, Jessup K, Floyd M. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. Transplantation 1980; 29: 290–4
- De Abreu RA, Van Baal JM, Schouten T J., Schretlen E DAM, De Bruyn C HMM. High-performance liquid chromatographic determination of plasma 6-mercaptopurine in clinically relevant concentrations. J Chromatogr 1982; 227: 526–33
- Schouten T J., De Abreu R A., De Bruyn C HMM. 6-Mercaptopurine: pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol 1984; 165B: 367–70
- Wagner J G. Fundamentals of clinical pharmacokinetics. First ed. Drug Intelligence Publications, Hamilton 1975
- Hyslop R M., Jardine I. Metabolism of 6-thiopurines. I. Irreversible binding of a metabolite of 6-thio-purine to mammalian hepatic protein in vitro. J Pharmacol Exp Ther 1981; 218: 621–8
- Hyslop R M., Jardine I. Metabolism of 6-thiopurines. II. Covalent binding of a 6-thiopurine metabolite to mammalian tissue protein in vivo. J Pharmacol Exp Ther 1981; 218: 629–35
- Sjöholm I, Stjerna B. Binding of drugs to human serum albumin XVII: Irreversible binding of mercaptopurine to human serum proteins. J Pharm Sci 1981; 70: 1290–1
- Tidd D M., Paterson A RP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34: 738–46
- Ding T L., Benet L Z. Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. Drug Metab Dispos 1979; 7: 373–7
- Zimm S, Collins J M., Riccardi R. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered. N Engl J Med 1983; 308: 1005–9
- Narang P K., Chatterji D C., O'Neill D, Poplack D G. Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cer-ebrospinal fluid following i.v. bolus. Drug Metab Dispos 1983; 11: 5–9
- Wotring L L., Roti Roti J L. Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity. Cancer Res 1980; 40: 1458–62
- Schouten T J., De Abreu R A., Schretlen E DAM, Van Baal J M., Van Leeuwen M B., De Vaan G AM. 6-Mercaptopurine: high-dose 24 hours infusions in goats (submitted)
- Mellett L B. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 1977; 61: 527–31